Phase 3 Immunodeficiency Clinical Trials
10 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled81 locationsNCT07044297
Recruiting
Phase 2Phase 3
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled56 locationsNCT07266831
Recruiting
Phase 3
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled30 locationsNCT07071623
Recruiting
Phase 3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Multiple MyelomaSecondary Immunodeficiency
Takeda183 enrolled28 locationsNCT06980480
Recruiting
Phase 3
Cefixime Clinical Trial
Human Immunodeficiency VirusSyphilis
University of Southern California400 enrolled1 locationNCT04958122
Recruiting
Phase 3
Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)
Primary Immunodeficiency Diseases
Biopharma Plasma LLC56 enrolled12 locationsNCT07346859
Recruiting
Phase 3
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
ObesityHIV (Human Immunodeficiency Virus)Overweight and/or Obesity
José Antonio Mata Marín306 enrolled1 locationNCT07075146
Recruiting
Phase 3
V+PSF-M for Tobacco Cessation in HIV Care in India
Smoking CessationSmoking, TobaccoHuman Immunodeficiency Virus
University of Colorado, Denver400 enrolled2 locationsNCT05786547
Recruiting
Phase 3
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
Primary Immunodeficiency Diseases (PID)
Takeda39 enrolled5 locationsNCT06076642
Recruiting
Phase 3
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
TuberculosisHuman Immunodeficiency Virus
Stellah Mpagama414 enrolled1 locationNCT05575518